(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 76.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Cue Biopharma's revenue in 2024 is $5,490,000.On average, 4 Wall Street analysts forecast CUE's revenue for 2024 to be $436,914,264, with the lowest CUE revenue forecast at $38,914,653, and the highest CUE revenue forecast at $1,319,693,163. On average, 3 Wall Street analysts forecast CUE's revenue for 2025 to be $726,390,638, with the lowest CUE revenue forecast at $38,914,653, and the highest CUE revenue forecast at $1,945,732,640.
In 2026, CUE is forecast to generate $1,575,070,572 in revenue, with the lowest revenue forecast at $194,573,264 and the highest revenue forecast at $4,256,290,150.